宫颈鳞癌新辅助化疗前后P-gp、MRP1、Survivin 对临床疗效的预测作用  

The Prediction of P-gp,MRP1 and Survivin in Cervical Squamous Cell Carcinoma before and after Neoadjuvant Chemotherapy

作　　者：陈芬[1,2] 彭瑞宇 王亚林 张丽萍 CHEN Fen;PENG Ruiyu;WANG Yalin(Taihe Hospital,Hubei College of Medicine,Shiyan City,Hubei Province 442000)

机构地区：[1]湖北医药学院附属太和医院,湖北省十堰市442000 [2]昆明爱维艾夫医院 [3]华中科技大学同济医院附属武汉儿童医院

出　　处：《医学理论与实践》2019年第20期3240-3242,3229,共4页The Journal of Medical Theory and Practice

摘　　要：目的:探讨在宫颈鳞癌患者中行新辅助化疗时,P-gp、MRP1、Survivin三种耐药相关蛋白对临床疗效的预测作用。方法:采用免疫组化S-P法和自动图像分析系统检测三种耐药相关蛋白:P-gp、MRP1、Survivin在30例Ⅰb2~Ⅱa期宫颈鳞癌患者新辅助化疗前后中的表达。结果:宫颈鳞癌新辅助化疗有效组P-gp阳性表达量显著低于无效组(P<0.01),且化疗后P-gp的阳性表达量显著高于化疗前水平(P<0.01);MRP1在宫颈鳞癌新辅助化疗有效组表达量低于无效组,但是差异无统计学意义(P>0.05),且化疗前后的阳性表达量亦无统计学意义(P>0.05);Survivin在宫颈鳞癌新辅助化疗有效组的表达量显著低于无效组(P<0.01),且化疗后Survivin的阳性表达量低于化疗前水平(P<0.05)。结论:P-gp、Survivin在一定程度上对宫颈鳞癌的新辅助化疗疗效可以起到积极的预测作用。Objective:To investigate the expression difference and the predictive role of P-gp,MRP1 and Survivin in cervical squamous cell carcinoma before and after Neoadjuvant chemotherapy.Methods:The expression of P-gp,MRP1 and Survivin were detected in 30 cases of invasive squamous cell cervical carcinoma in stage Ⅰb2~Ⅱa before and after NACT,in this retrospective study by immunohistochemical S-P method and pathological image computer analysis system.Results:The positive expression level of P-gp in the effective group was significantly lower than that in the invalid group after NACT(P<0.01), and the expression of P-gp after NACT is significantly higher than before(P<0.01);there was no correlation of the positive level of MRP1 between the effective and invalid group after NACT(P>0.05), and there was also no significant correlation between the expression of MRP1 before and after NACT(P>0.05);the positive expression level of Survivin in the effective group was significantly lower than that in the invalid group after NACT(P<0.01),and the expression of Survivin after NACT is significantly lower than before(P<0.01).Conclusion:The expression of P-gp and Survivin may be used to predictive the effiency of NACT.

关 键 词：宫颈鳞癌 新辅助化疗 P-糖蛋白 多药耐药相关蛋白1 生存素 免疫组织化学 

分 类 号：R737.33[医药卫生—肿瘤]